MPM Capital, the US-based life-sciences venture capital firm, has set up its seventh fund and raised $400m to invest in early-stage biotechs.
The focus of the fund, called BioVentures 2018, will be to tap into "disruptive scientific developments across multiple therapeutic areas,"...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?